Common bile duct calculi can be removed by endoscopic, percutaneous, or surgical means. In a minority of patients these approaches fail. This is usually because of technical difficulties, lar e stone size, or complicating medical problems. Direct infusion of bile duct stone solvents into the bile duct is a remaining therapeutic possibility in such patients. In addition, duct stones may be discovered by T-tube cholangiography within a few days after cholecystectomy. In such patients, stone solvents can be infused before the sinus tract has been formed, in which case mono-octanoin is an alternative to sphincterotomy. (Burhenne T-tract extraction cannot be carried out until a mature sinus tract has formed around the T-tube; this requires four to six weeks after placement of the T-tube.)
The practice of dissolving (cholesterol) bile duct stones by instilling organic cholesterol solvents into the gall bladder was described nearly a century ago.2 Pribram3 standardised the technique, and it was used commonly thereafter. 4 Nonetheless, the technique gradually fell into disfavour because of the severity of side effects in some patients, as well as improvement in surgical techniques.5 In 1972, Admirand and Way reported that a micellar solution of sodium cholate would dissolve cholesterol gall stones rapidly in vitro and could be used safely and effectively in patients with bile duct stones. 6 7 Early results of these workers and others"' were encouraging. Nonetheless, it was thought that success often resulted from the flushing effect per se of the cholate solution, as saline12 or a dilute heparin solution,'3 14 which has no ability whatsoever to dissolve cholesterol, has also been reported to cause stone disappearance when infused into T-tubes. In addition, toxicity studies in primates indicated 32 Coincident medical illness, recent biliary tract surgery, or endoscopic procedures did not preclude monooctanoin treatment. The physician was questioned to ensure that during cholangiography, dye flowed freely into the duodenum; if not, the treatment was approved only when no other approach was possible.
METHOD OF ADMINISTRATION
Mono-octanoin was shipped to the pharmacy of each medical centre. In the majority of patients, mono-octanoin was used as the anhydrous oil after sterile filtration. In some patients, however, the compound was used as received; mono-octanoin is bacteriostatic, and cultures for bacteria have been negative. During the past year, we have recommended that the pharmacist adds water to the mono-octanoin (10% by volume) to decrease its viscosity and lower its freezing point. In vitro studies have indicated that the addition of water should not decrease the solubility of cholesterol in mono-octanoin,33 and dissolution studies with model gall stones suggest that gall stones should dissolve more rapidly in mono-octanoin containing 10% water than in anhydrous mono-octanoin.30
Mono-octanoin warmed to approximately 37°C was infused through a T-tube, nasobiliary tube, percutaneous transhepatic catheter, or cholecystostomy tube into the biliary tract by using constant infusion pump or by gravity. In patients with an intact sphincter of Oddi and large common duct stones, precautions were taken to guard against the possibility that the stone might become impacted during mono-octanoin infusion and mono-octanoin would then be pumped into the biliary tract under pressure. Physicians were advised to place an overflow manometer in the tubing between the pump and the patient. A central venous pressure manometer was to be adjusted so that if the pressure exceeded 12 cm of mono-octanoin, the monooctanoin would overflow from the tube and not enter the patient. The initial infusion rate was I to 2 ml/h, and it was recommended that this should be increased to 5 ml/h. Nonetheless, in some studies, the infusion rates were twice this rate. Because each millilitre of mono-octanoin dissolves 120 mg of cholesterol, dissolution is likely to have occurred under 'sink' conditions -that is, the solvent was always almost completely unsaturated in cholesterol. In some patients, a concentric catheter was used, so that material could be infused even if a stone was impacted in the ampulla.34 In other patients, a two catheter arrangement was used to facilitate biliary drainage.21 35 As noted, however, physicians were advised that the use of mono-octanoin in patients with an obstructed common duct was quite hazardous, and such patients were approved only when no other therapeutic approach was possible. Cholangiograms were obtained before and at least at weekly intervals during the treatment period. Routine liver tests were monitored in most subjects. DEFINITION Table 2 ). Most of these were discovered by routine postoperative T-tube cholangiography. Eight patients were treated with mono-octanoin without complications less than two weeks after common duct exploration and, about 65% of patients were treated less than six weeks after a cholecystectomy.
Approximately one-third of subjects presented with retained common bile duct calculi more than six months after cholecystectomy (remote biliary surgery - Table 2 ). Many of these had undergone cholecystectomy several years previously, the longest period being 37 years.
A small group of subjects had not previously Serum alkaline phosphatase and aminotransferase concentrations were available in 261 patients before mono-octanoin infusion and in 173 patients at the completion of therapy. The majority of patients (69%) had a raised serum alkaliiie phosphatase concentration, and about half had a raised aminotransferase concentration before mono-octanoin infusion. In general, the subsequent course of these serum enzyme concentrations was not related to the outcome of treatment. In subjects in whom treatment was unequivocally successful, alkaline phos- phatase showed no consistent change.
SIDE EFFECTS OF MONO-OCTANOIN INFUSION
Side effects occurred in 67% of patients, and indeed, 41% of subjects had multiple side effects (Table 4) . Abdominal pain was the most common side effect and was the usual cause of aborted therapy. Pain was of three types. Most commonly it was described as burning in nature, was neither dose related, nor associated with increased biliary pressure. In some individuals, biliary type pain developed and was associated with increased manometric pressures. It was relieved by reducing the infusion rate. In a few individuals, severe acute biliary colic was precipitated by the infusion. This was assumed to be caused by impaction or passage of calculi at the ampulla of Vater. Nausea, vomiting, and diarrhoea were usually also dose related and responded to a reduction in the infusion rate. Fever occurred during the course of the infusion in 18 subjects. This was attributed to cholangitis, and bile cultures were positive in 15 of these patients. The usual organisms were enterobacteria, most commonly E coli and Strep faecalis. Pseudomonas and Klebsiella were cultured in a few cases. Infection with multiple organisms was common.
Severe side effects occurred in only 12 patients (5%). Life threatening haemorrhage from duodenal ulceration developed in one patient. Acute pancreatitis, probably because of gall stone impaction, occurred in two patients. Obstructive jaundice also caused by impaction at the ampulla developed in a further three subjects. One patient in whom an overflow manometer was inadvertently omitted developed acute pulmonary oedema. Another patient with cirrhosis developed systemic acidosis and encephalopathic signs.3 One patient had an (7.9) anaphylactoid reaction characterised by wheezing, rash, and hypotension. Septicaemia occurred in four patients. Leucopenia occurred in one patient.
Despite the variety and frequency of side effects, and despite the frail condition of many of the patients, no deaths were associated with monooctanoin infusion in these case reports.
Discussion
This study shows that mono-octanoin infusion is a moderately effective and usually safe treatment for bile duct calculi. This conclusion has also been stated by other authors, as noted, but previous studies have been based on much smaller patient samples.
The major deficiencies of this study are the lack of a control group and its multicentre basis. Less than one half of authorised physicians submitted case reports, and we cannot be certain that the response of the patients who were reported was identical to those who were not reported. A placebo group was not justified ethically. Spontaneous passage of moderately sized calculi from the biliary tree is unlikely, but some of the successful treatments were undoubtedly due to the flushing effect of the solvent per se.14 The results indicate that the common bile duct was cleared of stones in 34% of patients, either by mono-octanoin alone or by a combination of infusion therapy and an endoscopic or percutaneous procedure. Results with mono-octanoin are better than the results reported by others for sodium cholate811 or heparin solution."3 14 Only one controlled study has been done; Velasco et al14 showed that mono-octanoin is more effective than heparinised saline for dissolution of bile duct stones. The success rate might have been greater if treatment had been continued for longer in the group in whom treatment was only partially effective.
The efficacy of mono-octanoin infusion for retained bile duct stones is clearly less than that of endoscopic, percutaneous, or surgical techniques. The efficacy of these procedures cannot be compared with that of solvent infusions because the mono-octanoin was used when these alternatives had either failed or were not possible. Infusion -therapy was frequently used in the frail and elderly, and in these subjects, most of whom had previously undergone biliary surgery, the operative mortality would be anticipated to be quite high.37 A success rate of 34% with no mortality and a serious complication rate of 5% should be compared with the appreciable mortality of common duct exploration in subjects at high surgical risk.
Side effects were very frquent, but often resolved when the infusion rate was decreased. Monooctanoin directly damages the gastric and biliary epithelium of experimental animals,3840 and has been reported to cause mild mucosal irritation23 27 and possibly ulceration of the bile duct41 in man.
The drug therefore should be used with caution in subjects known to have peptic ulcer disease or in whom ischaemic bowel disease is suspected. Possibly the value of a mucosal protective agent, such as sucralfate, should be tested in a controlled study. Systemic acidosis and encephalopathy have been reported in a patient with severe parenchymal liver disease who received mono-octanoin.36 Presumably impaired hepatic uptake and/or oxidation of its hydrolysis product, octanoate, resulted in a greater load of octanoate into the systemic circulation.
In other patients, abdominal pain was produced by biliary tract distension. Such patients were unable to tolerate even very low rates of infusion and hourly aspiration and bolus injections of monooctanoin is an alternative treatment regimen in these individuals.
Other side effects were probably caused by the problems of the infusion technique, rather than the infusion material. Pancreatitis, obstructive jaundice, cholangitis, and septicaemia were almost certainly caused by gall stone impaction at the ampulla of Vater rather than by mono-octanoin itself, and possibly they could have been prevented by more careful monitoring of the biliary pressure. Crabtree and coworkers have reported a case of necrotising choledochomalacia after mono-octanoin was infused into the common duct of a patient with a common duct stone which appeared to have been obstructing the distal common duct intermittently. 42 The major factor decreasing efficacy when stones are effectively rinsed by solvent should be stone composition. As many as 40% of duct stones contain a major proportion of calcium salts,43 and treatment is likely to be ineffective in these. Alternating mono-octanoin with a solution of a chelating agent has been proposed by Leuschner et 
